[
    "bath was removed and the solution stirred at room temperature for 5 days. The reaction mixture was then poured into 200 g of crushed ice and the pH adjusted to 9.0 with 50% NaOH solution while maintaining the temperature below 35\u00b0C by adding ice as needed. The resulting precipitate was collected by filtration, washed with distilled water and dried under high vacuum overnight. The crude product was recrystallized from methylene chloride/hexane to yield 5-(N-phthalimidoaminomethyl-2,3,3-(3H)- trimethylindolenine (1) (30g, 63%). </p> Docosanyl 4-chlorobenzene sulfonate was prepared using a procedure described in PCT/US89/00087. \n\n Tetradecyl 4-chlorobenzene sulfonate was prepared in a similar fashion. 5-(N-phthalimido- aminomethyl)-2,3,3-(3H)-trimethylindolenine (6.36 g, 2 mmol) and tetradecyl-4-chlorobenzenesulfonate (7.62 g, 2 mmol) were combined and heated together at 130\u00b0C for 2 hours. The reaction mixture was then cooled to room temperature and the crude product recrystallized from ethyl acetate to yield pure 5-(N-phthalimido- aminomethyl)-1-tetradecyl-2,3,3-(3H)-trimethylindolenium 4-chlorobenzene sulfonate (2) (10.23 g. 72%), m.p. = 141\u00b0C. </p> 2,3,3-Trimethyl-(3H)-indolenine (6.26 g, 0.04 mol, Aldrich) and n-docosanyl-4-chlorobenzene sulfonate (20.02 g, 0.04 mol) were heated together at 140\u00b0C with stirring for 3 hours. The reaction mixture was then cooled to room temperature to give a waxy solid. The solid was then dissolved in ethanol (250 ml) and 200 ml of a saturated KI solution added and the solution stirred for 30 minutes. 1 liter of cold water was added and the stirring continued for a further 15 mins. The resulting precipitate was collected, washed twice with distilled water and dried under high vacuum overnight. The crude material was recrystallized from methylene chloride/hexane to yield pure 1-docosanyl-2,3,3-(3H) trimethyl-indolenium iodide (5) (14.5 g, 61%), m.p. = 107-110\u00b0C. </p> 1-docosanyl-2,3,3-(3H)-trimethylindolenium iodide (8.94 g, 0.015 mol), N,N-diphenylformamidine (2.94 g, 0.015 mol, Aldrich) and acetic anhydride (60 ml) were placed in a round bottomed flask fitted with a condensor and the flask was purged with argon and then the condenser fitted with a drying tube. The flask was placed in a preheated oil bath (160\u00b0C) and refluxed for 60 mins. The flask was then removed from the oil bath and cooled to room temperature. It was then transferred to a 1 liter Erlenmeyer flask and diluted with ethanol (60 ml) followed by 60 ml of a saturated KI solution and \n\n the mixture stirred for 30 mins. Cold water (800ml) was added and the stirring continued for a further 15 mins. The precipitated product was collected by filtration, washed with distilled water and dried under high vacuum overnight to yield 2-(\u03b2-acetonilidovinyl)-1-docosanyl- 3,3-(3H)dimethylindolenium iodide (6) (10.52 g, 95%), m.p.=98-100\u00b0C. The crude product was used without further purification. </p> 5-(N-phthalimidoaminomethyl)-1-tetradecyl-2,3,3- (3H)-trimethylindolenium 4-chlorobenzene-sulfonate (2) (14.1 g, 20 mmol) was dissolved in 300 ml of </p>concentrated HCl. The solution was slowly heated to 115\u00b0C (caution, may froth) and refluxed for 22 hours. After this time the mixture was cooled to room </p>temperature and. placed in an ice bath. The pH was adjusted to 9.0 with ammonium hydroxide (30%) while maintaining the temperature between 15 and 20\u00b0C. The solution was then diluted to twice its volume with distilled water and extracted with methylene chloride (3 X 200 ml). The methylene chloride extracts were </p>combined, dried over magnesium sulfate, and concentrated to provide 5-aminomethyl-3,3-dimethyl-2-methylene-1- tetradecyl-indoline as a yellow oil (3) (6.9 g, 90%). </p> 5-aminomethyl-3,3-dimethyl-2-methylene-1- tetradecyl-indoline (14.88 g, 38.75 mmol) was dissolved in methyl formate (75 ml) and heated to reflux (55\u00b0C) under argon for 24 hours. The solution was then cooled to room temperature and the methyl formate evaporated. The residue was recrystallized from hexane to yield 5- (N-formylaminomethyl)-3,3dimethyl-2-methylene-1- tetradecyl-indoline (4) (10.85 g, 68%). </p> 2-(\u03b2-acetonilidovinyl)-1-docosanyl-3,3-(3H)- dimethylindolenium iodide (6) (740 mgs, 1 mmol) and 5- (N-formylaminomethyl)-3,3-dimethyl-2-methylene-1- tetradecyl-indoline (4) (330 mg, 0.8 mmol) and anhydrous sodium acetate (150 mg, 1.8 mmol) were dissolved in isopropanol and stirred at room temperature for 24 \n\n hours. The solution was then transferred to a 250 ml Erlenmeyer flask, diluted with ethanol (20 ml) and a saturated solution of KI (20 ml), and the mixture stirred for 30 minutes. The product was precipitated out by the addition of 100 ml of cold water and the resulting solution stirred for 15 minutes. The </p> precipitate was collected by filtration, washed with distilled water and dried under high vacuum overnight. The crude product (870 mg) was split into two batches and each purified by flash column chromatography (silica gel, 10% isopropanol in methylene chloride) to yield pure 1'-docosanyl-5(N-formylaminomethyl)-1-tetradecyl- 3,3,3',3'tetramethylindocarbocyanine iodide (7) (414 mg, 52%). </p> 100 mis of a concentrated HCl:methanol solution</p>(prepared by mixing 11 ml of concentrated HCl and 120 mis of methanol) was added to 1'-docosanyl-5-(N\u2014 </p> formylaminomethyl)-1-tetradecyl-3,3,3',3'- tetramethylindocarbocyanine iodide (7) (250 mgs) and the solution stirred at room temperature for 16-24 h. The solution was then diluted with ice water (100 ml), cooled in an ice bath and taken to pH 7.5-8.0 by the slow addition of saturated sodium bicarbonate solution. The aqueous phase was then extracted with methylene chloride (2 x 100 ml) and the combined organic phases dried over sodium sulfate, filtered, concentrated (Buchi bath temp. &lt;30\u00b0C) and then dried under high vacuum to give product (8) (240 mgs, 98%) </p> b. 2-[3-(2,3-dihydro-3,3-dimethyl-5- aminomethyl-1-tetradecyl-(2H)-indol-2-yliden)-1- propenyl]-1-docosanyl-benzoxazolium iodide </p> The title compound was also prepared according to Reacti",
    "usly described, was heated at 160-170\u00b0C (oil bath temperature) for 6h. After this time, the reaction mixture was cooled to room temperature and the resulting solid mass recrystallized from methylene chloride to give pure 1-docosanyl-2-methylbenzoxazolium-4- chlorobenzene sulfonate (5) (7.3g, 58%), m.p.=124-125\u00b0C. </p> A stirred solution of 1-docosanyl-2-methyl- benzoxazolium 4-chlorobenzenesulfonate (5) (1.5 g, 2.36 mmol), N,N'-diphenyl-formamidine (0.462 g, 2.36 mmol, Aldrich) and acetic anhydride (7 ml) was refluxed in an oil bath (preheated to 160\u00b0C) for 30 mins. Upon cooling to room temperature, the mixture was diluted with absolute ethanol (15 ml) followed by a saturated </p>solution of potassium iodide (10 ml) and stirred for 30 mins. Water (150 ml) was then added and the </p>precipitated product collected by filtration, washed with water and dried under high vacuum overnight. The dried crude product was recrystallized from ethyl acetate to yield pure 2-(\u03b2-acetonilido-vinyl)-1- docosanyl-benzoxazolium iodide (6) (1.51 g, 90%), m.p.=67-68\u00b0C. </p> 2-(\u03b2-acettnilidovinyl)-1-docosanyl-benzoxazolium iodide (6) (1.10 g, 1.53 mmol), 5-(N-formylaminomethyl)-1-tetradecyl-3,3-dimethyl-2-methylene indoline (4) (630 mgs, 1.53 mmol), prepared as in 3a., above, triethylamine (0.5 ml) and ethanol (25 ml) were heated at reflux for 1 hour. The solution was then cooled to room temperature, transferred to a Erlenmeyer flask and then diluted with ethanol (40 ml) and a saturated solution of KI (20 ml). This mixture was stirred for 30 minutes then 200 ml of cold water was added and this solution extracted with methylene chloride. The \n\n methylene chloride extracts were combined, dried over magnesium sulfate, filtered and concentrated to give a crude product. This product was purified by flash column chromatography (silica gel, 5% methanol in methylene chloride) to yield 2-[3-(2,3-dihydro-3,3- dimethyl-5-(N-formylaminomethyl)-1-tetradecyl-(2H)- indol-2-yliden)-1-propenyl]-1-docosanyl-benzoxazolium iodide (7) (305 mgs, 20%). </p> 25 mis of a concentrated HCl:methanol solution, prepared as in a, above, was added to 2-[3-(2,3-dihydro- 3,3-dimethyl-5-(N-formylaminomethyl)-1-tetradecyl-(2H)- indol-2-yliden)-1-propenyl]-1-docosanyl-benzoxazolium iodide (7) (50 mgs) and the solution stirred at room temperature for 16-24 hours. The solution was then diluted with ice water (30 ml), cooled in an ice bath and adjusted to pH 7.5-8.0 by the slow addition of saturated sodium bicarbonate solution. The aqueous phase was then extracted with methylene chloride (2 x 50 ml) and the combined organic phases dried over sodium sulfate, filtered concentrated (Buchi bath temp. 0-5\u00b0C) and then dried under high vacuum to provide product (8) (48 mgs, 99%). </p> c. Terephthaloyl N-Hydroxyl succinimide Ester Derivative of 5-aminomethyl-1'-docosanyl-1-tetradecyl- 3,3,3',3'-tetramethylindocarbocyanine iodide </p> To a stirred solution of the di-N- hydroxysuccinimide ester of terephthalic acid (10",
    "much as concurrently assayed samples of serially diluted ghost-free </p>supernatants (\u0394) had no thrombin inhibitory activity. Thus, the compound of the invention still retains potent antithrombin action even when bound to </p>biomembranes. </p> Various aspects of the present invention have been described and exemplified above in terms of certain preferred embodiments, namely, the synthesis and use of chemotherapeutic and radiotherapeutic antiproliferative compounds. However many other embodiments may be apparent to those skilled in the \n\nart. For example, other chemotherapeutic and </p>radiotherapeutic conjugates may be synthesized and used for treatment or assessment of a variety of disease states or pathological conditions. </p>Additionally, the compounds and methods of the invention may be applied to the development of site- selective delivery and retention of drugs of other classes, such as anti-bacterial, anti-fungal or anti- inflammatory agents. This invention, therefore, is not limited to the embodiments specifically described and exemplified, but is capable of variation and modification without departure from the scope of the following claims. \n\n</p><img id=\"imgf000120_0001\" path=\"imgf000120_0001.tif\" file=\"https://surechembl.org/api/assets/attachment/174662553/WO/19930610/A1/001993/01/11/20/imgf000120_0001.tif\"/></p> Reogents: (i) Alkyl 4-chIorobenzene suIfonate </p> (ii) c.HCI (iii) HCO<sub>2</sub>Me </p> (iv) N ,N-diphenyIformamidine, Ac<sub>2</sub>O</p>(v) NaOAc, Ki (vi) MeOH-HCI \n\n</p><img id=\"imgf000121_0001\" path=\"imgf000121_0001.tif\" file=\"https://surechembl.org/api/assets/attachment/174662554/WO/19930610/A1/001993/01/11/20/imgf000121_0001.tif\"/></p><img id=\"imgf000122_0001\" path=\"imgf000122_0001.tif\" file=\"https://surechembl.org/api/assets/attachment/174662555/WO/19930610/A1/001993/01/11/20/imgf000122_0001.tif\"/></p>REAGENTS: (i) GLUTARIC ACID MONOMETHYL ESTER, DCC, NHS </p> (ii) HYDRAZINE (iii) GLUTARIC ANHYDRIDE (iv) CD! THEN Bu<sub>4</sub>NBH<sub>4</sub> (v) PCC \n\n\n<img id=\"imgf000123_0001\" path=\"imgf000123_0001.tif\" file=\"https://surechembl.org/api/assets/attachment/174662557/WO/19930610/A1/001993/01/11/20/imgf000123_0001.tif\"/>\n </p>REAGENTS: (i) TRIPHOSGENE (ii) SODIUM HEPARIN \n\n\n<img id=\"imgf000124_0001\" path=\"imgf000124_0001.tif\" file=\"https://surechembl.org/api/assets/attachment/174662559/WO/19930610/A1/001993/01/11/20/imgf000124_0001.tif\"/>\n \n\n\n<img id=\"imgf000125_0001\" path=\"imgf000125_0001.tif\" file=\"https://surechembl.org/api/assets/attachment/174662561/WO/19930610/A1/001993/01/11/20/imgf000125_0001.tif\"/>\n \n</p>"
]